UPDATE: Cantor Fitzgerald Starts Ionis Pharmaceuticals (IONS) at Neutral

(updated to add analyst name, price target and comment)

Cantor Fitzgerald analyst Eliana Merle initiates coverage on Ionis Pharmaceuticals (NASDAQ: IONS) with a Neutral rating, price target $68.00.

The analyst comments "Shares are up 50% YTD (vs. SPX 13%) which we think reflects high investor expectations for the base business and pipeline. We think near-term competitive headwinds to Spinraza, Ionis’ single largest revenue driver, are not reflected in the current valuation. We see growth potential from the neurology pipeline, such as Huntington’s and ALS, but we view these as high risk and competitive spaces."

For an analyst ratings summary and ratings history on Ionis Pharmaceuticals click here. For more ratings news on Ionis Pharmaceuticals click here.

Shares of Ionis Pharmaceuticals closed at $86.14 yesterday.

You May Also Be Interested In

• Cantor Fitzgerald Starts Nuvation Bio Inc (NUVB) at Overweight
• ICICI Securities Resumes Dalmia Bharat Ltd (DALBHARA:IN) at Add (2)
• Apple Hospitality REIT (APLE) Reiterated at Overweight by Cantor Fitzgerald: Set up for Growth